Nivalis Therapeutics, Inc., a pharmaceutical company, focuses on the discovery and development of product candidates for patients with cystic fibrosis in the United States. Its lead product candidate is N91115, a small molecule inhibitor, which is in Phase II clinical trial that addresses a defect in cystic fibrosis transmembrane conductance regulator resulting from mutations. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.

Alpine Immune Sciences Inc

Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO.

Should you buy, sell, or hold Alpine Immune Sciences Inc (ALPN) ?

Alpine Immune Sciences Inc (ALPN) : Buy or Sell